{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:09:59Z","timestamp":1787062199282,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1465-9921-12-40","type":"journal-article","created":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T17:30:06Z","timestamp":1302283806000},"source":"Crossref","is-referenced-by-count":96,"title":["Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review"],"prefix":"10.1186","volume":"12","author":[{"given":"Marie","family":"Westwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bourbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cerulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorana","family":"Capkun-Niggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"1072_CR1","unstructured":"Global initiative for chronic obstructive lung disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. Updated 2009. [accessed 10 June 2010]., [ http:\/\/www.goldcopd.com ]"},{"issue":"suppl 1","key":"1072_CR2","first-page":"1","volume":"59","author":"National Institute for Clinical Excellence","year":"2004","unstructured":"National Institute for Clinical Excellence: Chronic Obstructive Pulmonary Disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004, 59 (suppl 1): 1-232.","journal-title":"Thorax"},{"issue":"6","key":"1072_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992, 145 (6): 1321-1327.","journal-title":"Am Rev Respir Dis"},{"issue":"8","key":"1072_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","volume":"118","author":"GHF Guyatt","year":"1993","unstructured":"Guyatt GHF, Patrick DL: Measuring health-related quality of life. Ann Intern Med. 1993, 118 (8): 622-629.","journal-title":"Ann Intern Med"},{"key":"1072_CR5","first-page":"11","volume":"5","author":"E Stahl","year":"2001","unstructured":"Stahl E, Wadbo M, Bengtsson T, Strom K, Lofdahl KC-G: Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. J Outcomes Res. 2001, 5: 11-24.","journal-title":"J Outcomes Res"},{"key":"1072_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2288-5-14","volume":"5","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Kuderer NM: The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005, 5: 14-10.1186\/1471-2288-5-14.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1072_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW: St. George's Respiratory Questionnaire: MCID. COPD. 2005, 2 (1): 75-79. 10.1081\/COPD-200050513.","journal-title":"COPD"},{"issue":"1","key":"1072_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1081\/COPD-200050666","volume":"2","author":"DA Mahler","year":"2005","unstructured":"Mahler DA, Witek JTJ: The MCID of the Transition Dyspnea Index is a total score of one unit. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2005, 2 (1): 99-103. 10.1081\/COPD-200050666.","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"key":"1072_CR9","unstructured":"The Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions. Edited by Higgins JPT, Green S. Version 5.0.2, updated September 2009. [accessed 30th November 2010]. , [ http:\/\/www.cochrane-handbook.org ]"},{"issue":"1","key":"1072_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF: Minimal clinically important differences in COPD lung function. COPD. 2005, 2 (1): 111-124. 10.1081\/COPD-200053377.","journal-title":"COPD"},{"issue":"8","key":"1072_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","volume":"146","author":"SD Aaron","year":"2007","unstructured":"Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society\/Canadian Respiratory Clinical Research Consortium: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med. 2007, 146 (8): 545-555.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1072_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clinthera.2007.02.009","volume":"29","author":"RA Baumgartner","year":"2007","unstructured":"Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP: Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007, 29 (2): 261-278. 10.1016\/j.clinthera.2007.02.009.","journal-title":"Clin Ther"},{"issue":"5","key":"1072_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/thorax.58.5.399","volume":"58","author":"V Brusasco","year":"2003","unstructured":"Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003, 58 (5): 399-404. 10.1136\/thorax.58.5.399.","journal-title":"Thorax"},{"issue":"9356","key":"1072_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","volume":"361","author":"P Calverley","year":"2003","unstructured":"Calverley P, Pauwels R, Vestbo J, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003, 361 (9356): 449-456. 10.1016\/S0140-6736(03)12459-2.","journal-title":"Lancet"},{"issue":"8","key":"1072_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PMA Calverley","year":"2007","unstructured":"Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med. 2007, 356 (8): 775-789. 10.1056\/NEJMoa063070.","journal-title":"New Engl J Med"},{"issue":"12","key":"1072_CR16","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.rmed.2005.08.016","volume":"99","author":"M Campbell","year":"2005","unstructured":"Campbell M, Eliraz A, Johansson G, Tornling G, Nihl\u00e9n U, Bengtsson T, Rabe KF: Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005, 99 (12): 1511-1520. 10.1016\/j.rmed.2005.08.016.","journal-title":"Respir Med"},{"issue":"2","key":"1072_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1183\/09031936.02.00269802","volume":"19","author":"R Casaburi","year":"2002","unstructured":"Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002, 19 (2): 217-224. 10.1183\/09031936.02.00269802.","journal-title":"Eur Respir J"},{"issue":"8","key":"1072_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1155\/2007\/192961","volume":"14","author":"CKN Chan","year":"2007","unstructured":"Chan CKN, Maltais F, Sigouin C, Haddon JM, Ford GT: A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J. 2007, 14 (8): 465-472.","journal-title":"Can Respir J"},{"issue":"3","key":"1072_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1155\/2002\/493296","volume":"9","author":"KR Chapman","year":"2002","unstructured":"Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, Kuipers AF: The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J. 2002, 9 (3): 178-185.","journal-title":"Can Respir J"},{"issue":"5","key":"1072_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","volume":"164","author":"R Dahl","year":"2001","unstructured":"Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 164 (5): 778-784.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1072_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1378\/chest.122.1.47","volume":"122","author":"JF Donohue","year":"2002","unstructured":"Donohue JF, Van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002, 122 (1): 47-55. 10.1378\/chest.122.1.47.","journal-title":"Chest"},{"issue":"2","key":"1072_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2007.10.007","volume":"102","author":"NJ Gross","year":"2008","unstructured":"Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K: Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008, 102 (2): 189-197. 10.1016\/j.rmed.2007.10.007.","journal-title":"Respir Med"},{"issue":"4","key":"1072_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","volume":"155","author":"PW Jones","year":"1997","unstructured":"Jones PW, Bosh TK: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997, 155 (4): 1283-1289.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1072_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","volume":"69","author":"SI Rennard","year":"2009","unstructured":"Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE: Efficacy and tolerability of budesonide formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: Results from a 1-year randomized controlled clinical trial. Drugs. 2009, 69 (5): 549-565. 10.2165\/00003495-200969050-00004.","journal-title":"Drugs"},{"issue":"4","key":"1072_CR25","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","volume":"121","author":"A Rossi","year":"2002","unstructured":"Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002, 121 (4): 1058-1069. 10.1378\/chest.121.4.1058.","journal-title":"Chest"},{"key":"1072_CR26","unstructured":"Sepracor Inc: Safety and efficacy of arformoterol tartrate inhalation solution in subjects with Chronic Obstructive Pulmonary Disease. Accessed 23\/06\/2010., [ http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00250679?term=COPD+AND+Sepracor&rank=1 ]"},{"issue":"2","key":"1072_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/thx.2004.033266","volume":"61","author":"RA Stockley","year":"2006","unstructured":"Stockley RA, Chopra N, Rice L: Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006, 61 (2): 122-128. 10.1136\/thx.2004.033266.","journal-title":"Thorax"},{"issue":"14","key":"1072_CR28","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","volume":"68","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M: Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008, 68 (14): 1975-2000. 10.2165\/00003495-200868140-00004.","journal-title":"Drugs"},{"issue":"15","key":"1072_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med. 2008, 359 (15): 1543-1554. 10.1056\/NEJMoa0805800.","journal-title":"New Engl J Med"},{"issue":"1","key":"1072_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15412550902724073","volume":"6","author":"DP Tashkin","year":"2009","unstructured":"Tashkin DP, Pearle J, Iezzoni D, Varghese ST: Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009, 6 (1): 17-25. 10.1080\/15412550902724073.","journal-title":"COPD"},{"issue":"2","key":"1072_CR31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/COPD.S2463","volume":"3","author":"AB Tonnel","year":"2008","unstructured":"Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M, TIPHON study group: Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008, 3 (2): 301-310.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1072_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-2005-919145","volume":"60","author":"KM Beeh","year":"2006","unstructured":"Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N, ATEM-Studiengruppe: Efficacy of tiotropium bromide (Spiriva\u00ae) in patients with chronic obstructive pulmonary disease (COPD) of different severities. Pneumologie. 2006, 60 (6): 341-346. 10.1055\/s-2005-919145.","journal-title":"Pneumologie"},{"issue":"4","key":"1072_CR33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","volume":"10","author":"G Boyd","year":"1997","unstructured":"Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997, 10 (4): 815-821.","journal-title":"Eur Respir J"},{"issue":"6","key":"1072_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.pupt.2005.02.013","volume":"18","author":"DD Briggs Jr","year":"2005","unstructured":"Briggs DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005, 18 (6): 397-404. 10.1016\/j.pupt.2005.02.013.","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"1072_CR35","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1378\/chest.118.5.1294","volume":"118","author":"R Casaburi","year":"2000","unstructured":"Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial. Chest. 2000, 118 (5): 1294-1302. 10.1378\/chest.118.5.1294.","journal-title":"Chest"},{"issue":"12 I","key":"1072_CR36","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1592\/phco.2005.25.12.1708","volume":"25","author":"H Covelli","year":"2005","unstructured":"Covelli H, Bhattacharya S, Cassino C, Conoscenti C, Kesten S: Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy. 2005, 25 (12 I): 1708-1718. 10.1592\/phco.2005.25.12.1708.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1072_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1753465808089455","volume":"2","author":"JF Donohue","year":"2008","unstructured":"Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP: Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008, 2 (2): 37-48. 10.1177\/1753465808089455.","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"1072_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1183\/09031936.06.00062705","volume":"27","author":"D Dusser","year":"2006","unstructured":"Dusser D, Bravo ML, Iacono P: The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006, 27 (3): 547-555. 10.1183\/09031936.06.00062705.","journal-title":"Eur Respir J"},{"key":"1072_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1465-9921-8-45","volume":"8","author":"D Freeman","year":"2007","unstructured":"Freeman D, Lee A, Price D: Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res. 2007, 8: 45-55. 10.1186\/1465-9921-8-45.","journal-title":"Respir Res"},{"issue":"3","key":"1072_CR40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3132\/pcrj.2008.00037","volume":"17","author":"G Johansson","year":"2008","unstructured":"Johansson G, Lindberg A, Romberg K, Nordstr\u00f6m L, Gerken F, Roquet A: Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Resp J. 2008, 17 (3): 169-175. 10.3132\/pcrj.2008.00037.","journal-title":"Prim Care Resp J"},{"issue":"4","key":"1072_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1378\/chest.115.4.957","volume":"115","author":"DA Mahler","year":"1999","unstructured":"Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999, 115 (4): 957-965. 10.1378\/chest.115.4.957.","journal-title":"Chest"},{"issue":"1","key":"1072_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pupt.2007.04.003","volume":"21","author":"J Moita","year":"2008","unstructured":"Moita J, Barbara C, Cardoso J, Costa R, Sousa M, Ruiz J, Santos ML: Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther. 2008, 21 (1): 146-151. 10.1016\/j.pupt.2007.04.003.","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"1072_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","volume":"143","author":"DE Niewoehner","year":"2005","unstructured":"Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, Cassino C, Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005, 143 (5): 317-326.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1072_CR44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1034\/j.1399-3003.2000.15e11.x","volume":"15","author":"JA Van Noord","year":"2000","unstructured":"Van Noord JA, De Munck DRAJ, Bantje TA, Hop WC, Akveld ML, Bommer AM: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000, 15 (5): 878-885. 10.1034\/j.1399-3003.2000.15e11.x.","journal-title":"Eur Respir J"},{"issue":"11","key":"1072_CR45","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","volume":"102","author":"C Vogelmeier","year":"2008","unstructured":"Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J: Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med. 2008, 102 (11): 1511-1520. 10.1016\/j.rmed.2008.07.020.","journal-title":"Respir Med"},{"issue":"1","key":"1072_CR46","first-page":"52","volume":"64","author":"JL Corhay","year":"2009","unstructured":"Corhay JL, Louis R: The UPLIFT study (Understanding Potential Long-term Impacts on Function with Tiotropium). Rev Med Liege. 2009, 64 (1): 52-57.","journal-title":"Rev Med Liege"},{"issue":"5","key":"1072_CR47","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1183\/09031936.02.00301702","volume":"20","author":"M Wadbo","year":"2002","unstructured":"Wadbo M, Lofdahl CG, Larsson K, Skoogh BE, Tornling G, Arwestr\u00f6m E, Bengtsson T, Str\u00f6m K: Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J. 2002, 20 (5): 1138-1146. 10.1183\/09031936.02.00301702.","journal-title":"Eur Respir J"},{"issue":"11","key":"1072_CR48","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1136\/thorax.56.11.880","volume":"56","author":"PW Jones","year":"2001","unstructured":"Jones PW: Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001, 56 (11): 880-887. 10.1136\/thorax.56.11.880.","journal-title":"Thorax"},{"issue":"9589","key":"1072_CR49","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0140-6736(07)61381-6","volume":"370","author":"PMA Calverley","year":"2007","unstructured":"Calverley PMA, Rennard SI: What have we learned from large drug treatment trials in COPD?. Lancet. 2007, 370 (9589): 774-785. 10.1016\/S0140-6736(07)61381-6.","journal-title":"Lancet"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-12-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1465-9921-12-40\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-12-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T20:43:54Z","timestamp":1712349834000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-12-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1186\/1465-9921-12-40","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"article-number":"40"}}